2,577 results on '"Sasaki, Koji"'
Search Results
352. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes
353. Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis
354. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
355. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance
356. Real‐life incidence of thrombotic events in leukemia patients treated with ponatinib
357. PS4-1 Phase II study of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia
358. Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
359. Risk Stratification in Hypomethylating Agent-Treated Patients With Myelodysplastic Syndromes: A Multivariate Model
360. MDS-531 Risk Stratification in Hypomethylating Agent-Treated Patients With Myelodysplastic Syndromes: A Multivariate Model
361. MDS-352 Myelodysplastic syndromes with concomitant SF3B1 mutation and deletion of the long arm of chromosome 5
362. MDS-363 Genomic Evolution of Patients With Myeloid Neoplasms and Known Antecedent Clonal Hematopoiesis
363. AML-727 Clinical Characteristics and Outcomes of NUP98 Rearrangement in Adults with Acute Leukemia
364. Myelodysplastic Syndromes With Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5
365. Genomic Evolution of Patients With Myeloid Neoplasms and Known Antecedent Clonal Hematopoiesis
366. Clinical Characteristics and Outcomes of NUP98 Rearrangement in Adults with Acute Leukemia
367. Correction to: Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study
368. Acoustic Analysis of Vocal Tract Using Auto-Mesh Generation of Finite Element Modeling
369. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
370. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
371. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients
372. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia
373. Clinical characteristics and outcomes of previously untreated patients with adult onset T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma with hyper‐CVAD based regimens
374. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper‐CVAD‐based regimens
375. Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor
376. Phase 2 Study of Low-Dose Clofarabine Plus Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome Who Have Relapsed or Are Refractory to Hypomethylating Agents
377. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual disease
378. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia
379. The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors.
380. High-grade neuroendocrine carcinoma of the bladder (large cell and small cell mixed): a literature review and case report of a rare bladder tumor
381. A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy
382. Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10−4 and higher
383. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia
384. Treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) following the discontinuation of tyrosine kinase inhibitors.
385. Outcomes of patients with newly diagnosed acute myeloid leukemia (AML) and hyperleukocytosis.
386. Phase 2 study of azacitidine (AZA) and venetoclax (VEN) as maintenance therapy for acute myeloid leukemia (AML) patients in remission.
387. A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).
388. A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
389. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update.
390. Acute myeloid leukemia with KMT2Ar and association with risk of bleeding and early mortality.
391. TP53 ‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis
392. Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia
393. Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects
394. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
395. Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
396. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
397. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials
398. Prediction of survival with intensive chemotherapy in acute myeloid leukemia
399. Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
400. Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.